Abstrato

Clinical efficacy of meglumine adenosine cyclophosphate combined with perindopril in treating patients with chronic heart failure

Shumin He, Lu Zhang, Fengqin Jiang

Objective: To study the clinical efficacy of meglumine adenosine cyclophosphate combined with perindopril in treating patients with chronic heart failure.

Methods: Three hundred and twelve patients with chronic heart failure were enrolled and divided evenly into an observation group and a control group according to treatment methods, one hundred and fifty-six patients in each group. Patients in the observation group were treated with meglumine adenosine cyclophosphate and perindopril, while patients in the control group received conventional treatment. Clinical efficacy, heart function, mobility, brain natriuretic peptide concentration, insulinlike growth factor 1 concentration and homocysteine level were taken as investigation indexes.

Results: The overall effective rate in the observation group was higher than that of the control group; the difference was statistically significant (P<0.05). Compared with the patients in the control group, patients in the observation group had smaller Left Ventricular End Systolic Diameter (LVESD), Left Ventricular End-Diastolic Diameter (LVEDD), Interventricular Septum Thickness (IVST), Left Ventricular Posterior Wall Thickness (LVPWT), High Left Ventricular Ejection Fraction (LVEF) and longer 6-min walking distance; the differences were statistically significant (P<0.05). The differences in N-Terminal pro-Brain Natriuretic Peptide (NT-pro BNP), Insulin-Like Growth Factor 1 (IGF 1) and Homocysteine (Hcy) of the two groups had no statistical significance before treatment (P>0.05). The NTpro BNP, IGF 1 and Hcy of both groups were better than after treatment compared to before treatment; the difference was statistically significant (P<0.05); the NT-pro BNP, IGF 1 and Hcy of the observation group were better than those of the control group after treatment (P<0.05).

Conclusions: Treating patients with chronic heart failure with meglumine adenosine cyclophosphate combined with perindopril can relieve clinical symptoms and has good clinical effects; hence it is worth clinical promotion.